Alzheimer's Disease
Conditions
Keywords
Alzheimer's Disease, Alzheimer's, Stem cell, Adipose-derived stem cells, ASC, ADSC
Brief summary
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?
Detailed description
Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal. The therapy is composed of cells derived from a patients' own adipose tissue that are isolated within approximately 1 hour and immediately delivered back to the patient.
Interventions
PROCEDURELiposuction under local anesthesia
Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
BIOLOGICALInfusion of AD-SVF via IV and Intranasal
IV and Intranasal Infusion of isolated AD-SVF
Sponsors
Ageless Regenerative Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Males or females, age 55 or older * Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) Diagnostic and Statistical Manual of Mental Disorders (DSM IV) * Up to date on all age and gender appropriate cancer screening per American Cancer Society (Refer to section 9.3 for more details).
Exclusion criteria
* Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study * Life expectancy \< 6 months due to concomitant illnesses. * Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. * Active infectious disease. For patients who have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis ,then an expert will be consulted as to patient eligibility based on the patient's infectious status * Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results * Patients on chronic immunosuppressive transplant therapy * Systolic blood pressure (supine) ≤90 mmHg; * Resting heart rate \> 100 bpm; * Active clinical infection. * Cerebrovascular accident within 6 months prior to study entry * Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate. * History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years. * Patient or legal guardian if applicable us unwilling and/or not able to give written informed consent. * Dementia due to any condition other than AD, including vascular dementia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Improvement in Mini Mental State Examination (MMSE) | Six months after therapy | Improvement in MMSE six months after therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Event | One year after stem cell therapy | The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 12-months period following treatment. |
| Clinical Improvement in Functional Activities Questionnaire (FAQ) | Three and six months after therapy | — |
| Clinical Improvement in Activities of Daily Living Questionnaire (ADL) | Three and six months after therapy | — |
| Clinical Improvement in Geriatric Depression Scale (GDS) | Three and six months after therapy | — |
| Clinical Improvement in Mini Mental State Examination (MMSE) | Three months after therapy | — |
Countries
United States
Outcome results
None listed